Inogen Welcomes Three New Board Members

Inogen Inc. has appointed Glenn Boehnlein, Kevin King, and Mary Katherine Ladone to its Board of Directors. The trio replaces Heath Lukatch (director since 2006), Benjamin Anderson-Ray (director since 2013), and Loren McFarland (director since 2013), who have retired from the board.

“Heath, Ben and Loren’s partnership, input and guidance have been invaluable over their years of service to Inogen. I want to thank each of them for their commitment and for their many valuable contributions. Each of Heath, Ben, and Loren joined the Board while Inogen was a private company, and their tenure has notably included our initial public offering in 2014 and the continued development of innovative oxygen therapy solutions designed to improve the lives of patients worldwide,” Chairperson Elizabeth Mora said.
 
In connection with the new members’ appointments, Inogen reconstituted board committees. Boehnlein will chair the Audit Committee, King will chair the Compensation Committee, Heather Rider will chair the Nominating & Governance Committee, and Mora will chair the Compliance Committee. Inogen is maintaining the total of seven board members; the Director Classes are Rider and Mora in Class I, Shabshab, King, and Ladone in Class II, and Kristen Miranda and Boehnlein in Class III.
 
Boehnlein currently serves as vice president, chief financial officer (CFO) at Stryker Corporation. In this role, Boehnlein is responsible for global finance activities which include corporate accounting, reporting, tax, treasury, and internal audit. Additionally, he is also responsible for global information technology and investor relations. In 2003, Boehnlein began his career at Stryker as CFO for the Endoscopy division. Since then, he has served in roles of increasing responsibility at Stryker, including group CFO of MedSurg and Neurotechnology. Prior to joining Stryker, Boehnlein spent three years with MyPrimeTime as CFO, and prior to that, he was a partner and certified public accountant at Arthur Andersen.
 
Boehnlein earned a bachelor’s and master’s degree in accounting from Mississippi State University.
 
King has more than three decades of experience in the healthcare and IT industries in leadership roles. Until 2021, King served as CEO and president at iRhythm Technologies Inc.. He recently announced his retirement from iRhythm’s Board of Directors. 
Before joining iRhythm, King was president, CEO, and director of Affymetrix Inc. (now part of Thermo Fisher Scientific), a previously publicly-traded technology innovator in the field of genetic analysis, where he spent four years. Prior to joining Affymetrix in 2007, King served as president and CEO of Thomson Healthcare, an information services business, which focused on a range of healthcare-related businesses. King also held a number of senior executive positions at GE Healthcare and began his career in HP’s Medical Products Group.
 
King earned a bachelor’s degree in economics and biology from the University of Massachusetts and an M.B.A. from New Hampshire College. He also serves on the boards of two venture backed healthcare companies, Cleerly Health and Flosonics.
 
Ladone is an accomplished executive with more than 30 years of experience serving large global healthcare companies. Until January 2022, Ladone served as corporate officer and senior vice president, Corporate Development, Strategy & Investor Relations at Hill-Rom Holdings Inc., which is now a subsidiary of Baxter International Inc. Previously, Ladone served as senior vice president and corporate officer, Investor Relations, at Baxalta Inc., a global biopharmaceutical company spun out from Baxter International in 2015. She began her career in finance at Baxter International, and went on to serve in multiple financial, operational and communication roles of increasing responsibility at the company including leading Baxter’s investor relations between 2004 and 2015. 
 
Ladone has consistently been recognized by the investment community as a top investor relations professional, including numerous designations by Institutional Investor. She currently is a member of the Board of Directors of Bioventus Inc. Ladone earned a bachelor’s of Business Administration degree (Finance & Business Economics) cum laude from the University of Notre Dame.

“Maintaining a board with diverse, fresh perspectives, skills, and experience to drive shareholder value is of utmost priority for Inogen and we are thrilled to welcome Glenn, Kevin, and Mary Kay to the Inogen board,” Chairperson Elizabeth Mora said. “Each of them brings unique experiences and an extensive track record of helping guide and grow successful medtech companies, which we believe positions them to support our overarching goal of transforming Inogen into a prominent leader in respiratory care. Under the leadership of Nabil Shabshab, Inogen’s president and CEO, and his executive leadership team of industry veterans, we have continued to successfully execute on our strategic initiatives, including advancing our prescriber growth strategy and driving productivity and efficiency of our commercial operations. The addition of Glenn, Kevin and Mary Kay will further elevate the partnership between the Board and the executive team to advance Inogen’s transformation into a global respiratory care leader with durable and sustainable top-line growth and a path to bottom-line growth. On behalf of the entire Board and the executive leadership team, we welcome Glenn, Kevin and Mary Kay and look forward to working with them.”

Inogen is a medical technology company offering respiratory products for use in the homecare setting. The company develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.